Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avandia Meta-Analysis Problems Metastasize For FDA After JAMA Studies

Executive Summary

GlaxoSmithKline's Avandia (rosiglitazone) has become the chorus line to discussions of FDA's drug approval and oversight systems

You may also be interested in...



Adverse Event Surveillance Pilot From AHRQ Examines Hypertension, Diabetes

A study recently initiated by the Agency for Healthcare Research and Quality will develop a distributed network prototype by aggregating medical records and claims data for diabetes and hypertension therapy

Adverse Event Surveillance Pilot From AHRQ Examines Hypertension, Diabetes

A study recently initiated by the Agency for Healthcare Research and Quality will develop a distributed network prototype by aggregating medical records and claims data for diabetes and hypertension therapy

Bayer Trasylol Being Pulled From Market After BART Trial Fails As Tourniquet

Though Bayer's anti-bleeding drug Trasylol has survived the assault of observational study data and the scrutiny of two joint advisory panels, preliminary data from a randomized controlled trial has finally knocked the drug from the market

Related Content

UsernamePublicRestriction

Register

PS048784

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel